198 related articles for article (PubMed ID: 34543389)
1. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW; Sias-Garcia O; Daramola A; Wei H; Terrell M; Rashid R; Park WD; Duong K; Horton TM; Li F; Cherayil N; Koren JV; Gant VU; Junco JJ; Curry CV; Stevens AM; Lin CY; Yi JS
Blood Adv; 2021 Dec; 5(23):4864-4876. PubMed ID: 34543389
[TBL] [Abstract][Full Text] [Related]
2. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.
McKeown MR; Corces MR; Eaton ML; Fiore C; Lee E; Lopez JT; Chen MW; Smith D; Chan SM; Koenig JL; Austgen K; Guenther MG; Orlando DA; Lovén J; Fritz CC; Majeti R
Cancer Discov; 2017 Oct; 7(10):1136-1153. PubMed ID: 28729405
[TBL] [Abstract][Full Text] [Related]
3. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
de Botton S; Cluzeau T; Vigil C; Cook RJ; Rousselot P; Rizzieri DA; Liesveld JL; Fenaux P; Braun T; Banos A; Jurcic JG; Sekeres MA; Savona MR; Roboz GJ; Bixby D; Madigan K; Volkert A; Stephens K; Kang-Fortner Q; Baker K; Paul S; McKeown M; Carulli J; Eaton M; Hodgson G; Fiore C; Kelly MJ; Roth DA; Stein EM
Blood Adv; 2023 May; 7(9):1858-1870. PubMed ID: 36477975
[TBL] [Abstract][Full Text] [Related]
4. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with
Stein EM; de Botton S; Cluzeau T; Pigneux A; Liesveld JL; Cook RJ; Rousselot P; Rizzieri DA; Braun T; Roboz GJ; Lebon D; Heiblig M; Baker K; Volkert A; Paul S; Rajagopal N; Roth DA; Kelly M; Peterlin P
Leuk Lymphoma; 2023 Dec; 64(12):1992-2001. PubMed ID: 37571998
[TBL] [Abstract][Full Text] [Related]
5. Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
Fabiani E; Cicconi L; Nardozza AM; Cristiano A; Rossi M; Ottone T; Falconi G; Divona M; Testi AM; Annibali O; Castelli R; Lazarevic V; Rego E; Montesinos P; Esteve J; Venditti A; Della Porta M; Arcese W; Lo-Coco F; Voso MT
Cancer Med; 2021 Jun; 10(12):3839-3847. PubMed ID: 34042280
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Effects of the RAR
Fleischmann M; Bechwar J; Voigtländer D; Fischer M; Schnetzke U; Hochhaus A; Scholl S
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610989
[TBL] [Abstract][Full Text] [Related]
7. AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid.
Classen CF; Teigler-Schlegel A; Röttgers S; Reinhardt D; Döhner K; Debatin KM
Ann Hematol; 2005 Nov; 84(12):774-80. PubMed ID: 16044313
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
[TBL] [Abstract][Full Text] [Related]
9. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract][Full Text] [Related]
10. Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells.
Cieniewicz B; Uyeda MJ; Chen PP; Sayitoglu EC; Liu JM; Andolfi G; Greenthal K; Bertaina A; Gregori S; Bacchetta R; Lacayo NJ; Cepika AM; Roncarolo MG
Haematologica; 2021 Oct; 106(10):2588-2597. PubMed ID: 33054128
[TBL] [Abstract][Full Text] [Related]
11. Multiplex fusion gene testing in pediatric acute myeloid leukemia.
Iijima-Yamashita Y; Matsuo H; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Takahashi H; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):47-51. PubMed ID: 29105243
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.
Wang E; Aifantis I
Cancer Discov; 2017 Oct; 7(10):1065-1066. PubMed ID: 28974530
[TBL] [Abstract][Full Text] [Related]
13. Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives.
Chianese U; Papulino C; Megchelenbrink W; Tambaro FP; Ciardiello F; Benedetti R; Altucci L
Semin Cancer Biol; 2023 Jul; 92():84-101. PubMed ID: 37003397
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia.
Glasow A; Barrett A; Petrie K; Gupta R; Boix-Chornet M; Zhou DC; Grimwade D; Gallagher R; von Lindern M; Waxman S; Enver T; Hildebrandt G; Zelent A
Blood; 2008 Feb; 111(4):2374-7. PubMed ID: 17993618
[TBL] [Abstract][Full Text] [Related]
15. A novel NUP98-JADE2 fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia.
Cheng CK; Chan HY; Yung YL; Wan TSK; Leung AWK; Li CK; Tian K; Chan NPH; Cheung JS; Ng MHL
Blood Adv; 2022 Jan; 6(2):410-415. PubMed ID: 34673934
[TBL] [Abstract][Full Text] [Related]
16. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
Zhao J; Liang JW; Xue HL; Shen SH; Chen J; Tang YJ; Yu LS; Liang HH; Gu LJ; Tang JY; Li BS
Leukemia; 2019 Jun; 33(6):1387-1399. PubMed ID: 30575821
[TBL] [Abstract][Full Text] [Related]
17. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the RARA gene in acute myeloid leukemia: significant finding or coincidental observation?
Asleson AD; Morgan V; Smith S; Velagaleti GV
Cancer Genet Cytogenet; 2010 Oct; 202(1):33-7. PubMed ID: 20804918
[TBL] [Abstract][Full Text] [Related]
19. Eya2, a Target Activated by Plzf, Is Critical for
Ono R; Masuya M; Ishii S; Katayama N; Nosaka T
Mol Cell Biol; 2017 Jul; 37(13):. PubMed ID: 28416638
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
